SAN DIEGO, December 1, 2015 /PRNewswire/ – Profil Institute for Clinical Research, a clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today the addition of Christian Weyer, M.D., M.A.S. to its executive management team as President and Chief Development Officer. Dr. Weyer was most recently President and CEO of Fate Therapeutics. Prior to that he held a number of senior leadership positions at Amylin Pharmaceuticals where he contributed to the development and approval of several first-in-class medicines for diabetes and lipodystrophy, while also leading the company’s programs and global strategic partnership in obesity. Dr. Marcus Hompesch will continue to lead Profil Institute as the company’s CEO and Chairman of the Board.
Dr. Weyer’s career in metabolic drug development spans more than 20 years, involving clinical studies and regulatory submissions at all stages of product development and across the continuum of diabetes, obesity and NAFLD/NASH. In the newly created role of Chief Development Officer, Dr. Weyer will oversee the company’s clinical development services and forge new strategic partnerships with biopharmaceutical companies and other stakeholder groups pursuing clinical development programs or licensing opportunities for metabolic drug or device candidates.
“Building upon its long-standing scientific reputation, therapeutic focus, track record of clinical trial execution, and growing network of metabolic research partners, Profil Institute is uniquely positioned to further expand its global leadership as the partner of choice for metabolic R&D,” said Dr. Weyer. “I’m excited to join the Company during this next stage of strategic expansion, as we work to offer clients worldwide an unrivaled and comprehensive suite of clinical research and development services to enable efficient and expeditious paths to value creation.”
“We are excited to welcome Chris to our leadership team during this time of dynamic growth,” said Dr. Hompesch. “Chris’ career leading drug development programs and global pharmaceutical partnerships, in addition to his deep scientific expertise in metabolic research, makes him an ideal addition to the leadership team at Profil Institute. Chris will be instrumental as we expand our clinical development consulting services for clients seeking a science-driven, therapeutically focused CRO with a proven track record of facilitating clinical, regulatory and licensing strategies.”
Dr. Weyer is globally recognized as an accomplished business leader with scientific expertise in diabetes and obesity through his work in academia, government research, and the biopharmaceutical settings. Following training at the Department of Metabolic Disorders, World Health Organization Collaborating Center for Diabetes Treatment and Prevention, at the University of Düsseldorf, Germany, Dr. Weyer worked at the National Institutes of Health, NIDDK, conducting clinical research on the pathogenesis of obesity and type 2 diabetes. During his subsequent 12-year tenure with Amylin Pharmaceuticals, he held a number of senior leadership positions in R&D and corporate development, serving most recently as Senior Vice President of R&D. Following Amylin’s acquisition by Bristol-Myers Squibb in August 2012, he joined Fate Therapeutics as President and CEO, where he steered the company’s transition into a publicly-traded cellular therapeutics company, advancing new programs and partnerships in immuno-oncology, inherited metabolic disorders and type 1 diabetes.
About Profil Institute for Clinical Research, Inc.
Profil Institute is an early engagement clinical research organization (CRO) exclusively focused on metabolic diseases, including diabetes, obesity and NAFLD/NASH. The company is recognized globally for its scientific expertise, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes. Profil Institute provides a full scope of CRO services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.
Profil Institute has completed more than 230 clinical trials focused on metabolism, including diabetes, obesity and NAFLD/NASH. Profil Institute is leveraging that deep expertise in metabolic disease to become the leading CRO pursuing solutions for the unmet medical needs of NAFLD/NASH patients.
Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices. The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.
Profil Institute is also widely recognized as an innovator of methodologies, including its Automated Glucose Clamp technology, and for driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners. For more information, please visit www.profilinstitute.com.
For further information, please contact:
+1 (858) 663-6148